Genomic Biomarkers Market Report 2026

Genomic Biomarkers Market Overview

• Genomic Biomarkers market size has reached to $8.72 billion in 2025 • Expected to grow to $19.33 billion in 2030 at a compound annual growth rate (CAGR) of 17.2% • Growth Driver: Growth Of Genomic Biomarkers Market Driven By Personalized Medicine Demand • Market Trend: Advancements In Genomic Biomarkers To Enhance Precision Medicine In Lung Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Genomic Biomarkers Market?

Genomic biomarkers are specific sequences or variations in DNA or RNA that provide information about a biological process, condition, or response to a particular treatment. These biomarkers are used in precision medicine to predict disease risk, diagnose conditions, monitor disease progression, or guide treatment decisions. Genomic biomarkers are crucial for personalized medicine, allowing healthcare providers to tailor treatments based on an individual's genetic makeup, improving the effectiveness of therapies, and reducing the likelihood of adverse effects. The main types of genomic biomarkers are predictive biomarkers and prognostic biomarkers. Predictive biomarkers are biological molecules found in blood, other body fluids, or tissues that indicate whether a patient is likely to benefit from a particular medical treatment or intervention. The various disease indications include oncology, cardiovascular diseases, neurological diseases, renal disorders, and others with various validation such as analytical validation, clinical validation, and clinical utility. These are used by various end-users such as hospitals, diagnostic centers, and others.

What Is The Genomic Biomarkers Market Growth Forecast?

The genomic biomarkers market size is expected to see rapid growth in the next few years. It will grow to $19.33 billion in 2030 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to increasing investments in precision medicine programs, rising demand for early disease detection tools, expansion of biomarker-driven drug development, growing integration of ai in biomarker analysis, increasing regulatory support for personalized therapies. Major trends in the forecast period include increasing adoption of biomarker-guided precision medicine, rising integration of genomic data in clinical decision-making, growing use of companion diagnostics, expansion of multi-omics biomarker platforms, enhanced focus on clinical validation standards.

Global Genomic Biomarkers Market Segmentation

1) By Type: Predictive Biomarkers, Prognostic Biomarkers 2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications 3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility 4) By End-User: Hospitals, Diagnostic Centers, Other End-Users Subsegments: 1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility 2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers

What Is The Driver Of The Genomic Biomarkers Market?

The increasing demand for personalized medicine is expected to propel the growth of the genomic biomarkers market going forward. Personalized medicine, also known as precision medicine, is a medical approach that tailors healthcare decisions and treatments to the individual characteristics of each patient, primarily based on their genetic and genomic information. The increasing demand for personalized medicine is due to several factors, such as the growing emphasis on patient-centered care, genetic sequencing and analysis advances, a patient-centric approach, and the use of EHRs to store and analyze patient data. Genomic biomarkers play a crucial role in personalized medicine by enabling healthcare providers to tailor medical treatments to an individual’s unique genetic makeup. This approach, also known as precision medicine, aims to optimize the effectiveness of treatments and minimize side effects by considering the genetic differences between individuals. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing demand for personalized medicine drives the growth of the genomic biomarkers industry.

Key Players In The Global Genomic Biomarkers Market

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4

Global Genomic Biomarkers Market Trends and Insights

Major companies operating in the genomic biomarkers market are focused on developing innovative products, such as lung reagents, to enhance the detection of specific genetic mutations in lung cancer, improve diagnostic accuracy, and facilitate personalized treatment approaches by leveraging advanced genomic technologies. Lung reagents refer to specialized chemical or biological substances used in diagnostic tests, research, or medical procedures related to the lungs helping in precision medicine by guiding treatment choices based on the specific genetic profile of the cancer. For instance, in December 2023, Biofidelity, a UK-based company specializing in developing advanced genomic assays and precision diagnostics, launched ASPYRE-Lung reagents. The ASPYRE-Lung reagents are designed to identify key genetic mutations and alterations in lung cancer, which are critical for guiding targeted therapies and personalized treatment strategies.

What Are Latest Mergers And Acquisitions In The Genomic Biomarkers Market?

In October 2025, Guardant Health, Inc., a US-based precision oncology company, entered into a strategic partnership with Zephyr AI, Inc., a US-based precision medicine company specializing in artificial intelligence. Through this collaboration, the companies aim to accelerate the development of novel cancer biomarkers by integrating Guardant Health’s multimodal molecular and real-world oncology data with Zephyr AI’s advanced AI/ML analytics platform. Zephyr AI, Inc. applies artificial intelligence and machine learning technologies to support biomarker discovery, drug development, and personalized treatment strategies.

Regional Outlook

North America was the largest region in the genomic biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Genomic Biomarkers Market?

The genomic biomarkers market consists of sales of genomic biomarker panels, real-time PCR detection systems, and droplet digital PCR (ddPCR) systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Genomic Biomarkers Market Report 2026?

The genomic biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the genomic biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.